A team of Danish researchers believe that omega-3 bioavailability in fish oil supplements is dependent on the type of formulation. Their research was published in the September issue of Prostaglandins, Leukotrienes, and Essential Fatty Acids.
A team of Danish researchers believe that omega-3 bioavailability in fish oil supplements is dependent on the type of formulation. Their research was published in the September issue of Prostaglandins, Leukotrienes, and Essential Fatty Acids.
Fish oil was formulated using three different formulations: ethyl esters, free fatty acids, and reesterified triglycerides, compared to placebo. In a double-blind manner, bioavailable levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were then measured across the board.
EPA and DHA bioavailability was found to be superior from reesterified triglycerides (124%) compared to natural fish oil; meanwhile, ethyl esters were found to provide inferior bioavailability at 73% and free fatty acid (91%) did not differ significantly from natural fish oil.
Results of this study might bode well for a company like Nordic Naturals (Watsonville, CA), which offers fish oil in the form of reesterified triglycerides.
“In fish, [EPA and DHA] occur naturally in triglyceride form,” said the company in a recent press release. “To make a quality fish oil concentrate, the individual fatty acids must first be removed from the glycerol backbone. To stabilize these delicate fatty acids, they are bound to an ethyl alcohol molecule before they undergo molecular distillation to both purify and increase the amounts of EPA and DHA. Once the desired concentration is achieved, a manufacturer chooses from two distinctly different options. The first is to reattach the fatty acids to the glycerol backbone in a process known as “re-esterification” to recreate the natural triglyceride structure. The second, far less costly option is to leave the fish oil as an ethyl ester, a “new to nature” form of fatty acid.”
Check out the study abstract here.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.